zilovertamab,ibrutinib
oncternal therapeutics,janssen,abbvie,merck
['zilovertamab', 'ibru', '$onct']
$onct presents rationale and plans for its registrational phase 3 study evaluating zilovertamab in combination with ibrutinib at the eha 2022 congress 
Clinical pharmacist PharmD, BCPS | Not advice, just my opinions and a lot of dabble about Biotech | Tech | Defi (3, 3)